Dana-farber-cancer Institute Inc.

The Brigham and Women's Hospital, Inc.

Fox Chase Cancer Center

Burnham Institute for Medical Research

Other

New England Deaconess Hospital Corporation

The Bingham and Women's Hospital

Wayne A Marasco

Jianhua Sui

Quan Zhu

Chen Hui Xu

De-Kuan Chang

William A Haseltine

Thomas S Kupper

Agnes Lo

Sandra Ogueta

Yuval Avnir

Joseph G Sodroski

Gregory P Adams

Xianchun Tang

David B Ring

Chen Xu

Jennifer Richardson

Heidi H Simmons

Robert C Liddington

Qing-an Yuan

Smita Mehta

Marshall R Posner

Abner Mhashilkar

Elizabeth Baez

Si-Yi Chen

Xiangchun Tang

Julie Porter-Brooks

Urban Ramstedt

Bridget Eberhardt

Joyce Lavecchio

Maria Cristina Parolin

Emily Kuiper

Francesca Gennari

Matthew Chang

Robert Liddington

MUC1 is overexpressed in many cancers, including those of the lung, colon, breast, ovary, and pancreas. Aspects of the invention are directed towards the discovery of monoclonal antibodies and fragments thereof, such as a human single chain variable fragment (scFv), that recognizes human MUC1-SEA.

Antibodies against MUC1

The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.

Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof

This invention is directed to engineered cells and methods for using the same. In embodiments, the engineered cell comprises a nucleic acid encoding a chimeric antigen receptor and a polypeptide, wherein the chimeric antigen receptor is specific for two or more antigens on the surface of a cancer cell, and wherein the polypeptide comprises an antibody or fragment thereof that can be secreted from the engineered cell.

Engineered cells, T cell immune modulating antibodies and methods for using the same

The present invention provides chimeric antigen receptors, cells expressing same and methods of using same for treatment various disorders such as cancer.

Chimeric antigen receptors and methods of use thereof

The present invention provides structural determinants important for binding to the stem domain of the HA protein of influenza virus, and methods of use thereof for production of high affinity neutralizing influenza virus antibodies based upon these determinants. The present invention further provides tools for determining the efficacy of an influenza virus vaccine. The present invention further provides a molecular signature useful for determining the efficacy of an influenza virus vaccine in a subject, or for predicting prior immunologic exposure or antigen responsiveness to vaccine or influenza virus infection.

Humanized influenza monoclonal antibodies and methods of use thereof

The present invention provides chimeric antigen receptor cells specific for carbonic anhydrase IX (CAIX) and methods of using same for treatment of CAIX expressing cancers such as renal cell carcinoma.

Method of treating a tumor expressing carbonic anhydrase IX (G250) by administering a G250-specific chimeric antigen receptor

The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.

Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof

The present disclosure provides methods of modulating regulatory T-cell activity and function.

Methods for depleting or inhibiting the migration of regulatory T-cells in early or late stages of cancer

The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are the methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby.

Method of treating renal cancer using carbonic anhydrase IX (G250) antibodies

Immunogenetic restriction on elicitation of antibodies

The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor). Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.

Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof

The present invention provides antibodies that neutralize flavivirus and methods of use thereof. These antibodies are derived from mAbl 1 which recognizes West Nile virus E protein and is cross-reactive with members of the flavivirus family, including Denge virus. The antibodies of the present invention prevent antibody-dependent enhancement of a viral infection by having a modified Fc region that does not bind to the Fcy receptor. The invented antibody is used to treat flaviviral infections and symptoms thereof.

Flavivirus neutralizing antibodies and methods of use thereof

Chimeric antigen receptors specific for carbonic acid anhydrase IX

Growing community of inventors

Wellesley, MA, United States of America

Wayne A Marasco